An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders

M. Bennie, C. Black, V. Cairns, S. Hems, L. Mciver, J. Nicholson, S. Oduro, R. Payne, W. Ramsay

Research output: Contribution to journalConference Contributionpeer-review

32 Citations (Scopus)


A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug and
Therapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).
Original languageEnglish
Pages (from-to)92-92
Number of pages1
JournalBasic and Clinical Pharmacology and Toxicology
Issue numberSupp.1
Early online date26 Jun 2009
Publication statusPublished - Aug 2009
Event9th Congress of the European Association for the Clinical Pharmacology and Therapeutics - Edinburgh, United Kingdom
Duration: 12 Jul 200915 Jul 2009


  • medicine
  • Scotland
  • consortium
  • area drug and therapeutics committees
  • ADTCs

Cite this